GH and Childhood-onset Craniopharyngioma: When to Initiate GH Replacement Therapy?

Quoc, Adrien Nguyen; Beccaria, Kévin; Briceño, Laura González; Pinto, Graziella; Samara-Boustani, Dinane; Stoupa, Athanasia; Beltrand, Jacques; Besançon, Alix; Thalassinos, Caroline; Puget, Stéphanie; Blauwblomme, Thomas; Alapetite, Claire; Bolle, Stéphanie; Doz, François; Grill, Jacques; Dufour, Christelle; Bourdeaut, Franck; Abbou, Samuel; Guerrini-Rousseau, Léa; Leruste, Amaury

Context: Craniopharyngioma is a benign brain tumor with frequent local recurrence or progression after treatment. GH replacement therapy (GHRT) is prescribed in children with GH deficiency resulting from childhood-onset craniopharyngioma. Objective: To evaluate whether a shorter delay of GHRT initiation after childhood-onset craniopharyngioma completion therapy increased the risk of a new event (progression or recurrence). Methods: Retrospective, observational, monocenter study. We compared a cohort of 71 childhood-onset patients with craniopharyngiomas treated with recombinant human GH (rhGH). Twenty-seven patients were treated with rhGH at least 12 months after craniopharyngioma treatment (>12-month group) and 44 patients before 12 months (<12-month group), among which 29 patients were treated between 6 and 12 months (6-12 month group). The main outcome was the risk of tumor new event (progression of residual tumor or tumor recurrence after complete resection) after primary treatment in the >12-month group and in the <12 month or in the 6- to 12-month group patients. Results: In the >12-month group, the 2- and 5-year event-free survivals were respectively 81.5% (95% CI, 61.1-91.9) and 69.4% (95% CI, 47.9- 83.4) compared with 72.2% (95% CI, 56.3-83.1) and 69.8% (95% CI, 53.8-81.2) in the <12-month group. The 2- and 5-year event-free survivals were the same in the 6- to 12-month group (72.4%; 95% CI, 52.4-85.1). By log-rank test, the event-free survival was not different between groups (P = .98 and P = .91). The median time for event was not statistically different. In univariate and multivariate analysis, the risk of craniopharyngioma new event was not associated with the GHRT time delay after craniopharyngioma treatment. Conclusions: No association was found between GHRT time delay after childhood-onset craniopharyngioma treatment and an increased risk of recurrence or tumor progression, suggesting GH replacement therapy can be initiated 6 months after last treatment for craniopharyngiomas.

CRANIOPHARYNGIOMA; BENIGN tumors

Journal of Clinical Endocrinology & Metabolism, 2023, Vol 108, Issue 8, p1929

0021-972X

Academic Journal

10.1210/clinem/dgad079